Weekly Clinical Updates

Genome-wide Association Study of Susceptibility to Respiratory Syncytial Virus Hospitalization in Young Children <5 Years of age | Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines | Interim Effectiveness Estimates of 2023 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalizations | Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines | The C.D.C. Director Explains Why You Should Get the Latest Covid Booster | Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection : A Prospective Cohort Study | Optimal Duration of Systemic Corticosteroids in Coronavirus Disease 2019 Treatment: A Systematic Review and Meta-analysis | Timing and Predictors of Loss of Infectivity among Healthcare Workers with Mild Primary and Recurrent COVID-19: a Prospective Observational Cohort Study | Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: A randomized, double-blind, and placebo-controlled study

Temporal changes in fecal microbiota of patients infected with COVID-19: a longitudinal cohort | Mpox: China’s health authorities fight surge in cases of unknown origin | Comparison of bivalent and monovalent mRNA vaccine boosters | Prevalence and associated outcomes of co-infection between SARS-CoV-2 and influenza: a systematic review and meta-analysis

Human Neural Larva Migrans Caused by Ophidascaris robertsi Ascarid | The public health significance of finding autochthonous melioidosis cases | Clinical Outcomes Associated With Overestimation of Oxygen Saturation by Pulse Oximetry in Patients Hospitalized With COVID-19 | Project NextGen Awards Over $1.4 Billion to Develop the Future of COVID-19 Vaccines and Therapeutics | Differences in SARS-CoV-2 specific humoral and cellular immune responses | Pfizer and BioNTech Receive Positive CHMP (Committee for Medicinal Products for Human Use) Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union | Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV) | Optimal Duration of Systemic Corticosteroids in Coronavirus Disease 2019 Treatment | Excess All-Cause Mortality in China After Ending the Zero COVID Policy | International Pediatric COVID-19 Severity Over the Course of the Pandemic | Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination

FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants | Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 Influenza Season | Nirmatrelvir resistance – de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure – a case report | Progress Toward Poliomyelitis Eradication — Pakistan, January 2022–June 2023 | Modeling poliovirus transmission and responses in New York State | Incidence of New-Onset Hypertension Post–COVID-19: Comparison With Influenza | Postacute sequelae of COVID-19 at 2 years

Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019 (COVID-19) | The STOP COVID 2 study: Fluvoxamine vs placebo for outpatients with symptomatic COVID-19, a fully-remote randomized controlled trial | The effect of corticosteroids, antibiotics, and anticoagulants on the development of post-COVID-19 syndrome in COVID-19 hospitalized patients 6 months after discharge: a retrospective follow up study

Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study | Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts | Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial